LEO 80185 Gel (Calcipotriol Hydrate Plus Betamethasone Dipropionate) in Japanese Subjects With Psoriasis

Inclusion Criteria:

1. Informed consent has been obtained.

2. Japanese subjects

3. Aged 20 years or above

4. Clinical diagnosis of psoriasis vulgaris amenable to topical treatment of lessthan or equal to 30% BSA

5. A target psoriasis lesion on the scalp and on the non-scalp area of the body,each lesion of a minimum size of 10 cm2 and scoring at least 2 (mild) for eachof the clinical signs (redness, thickness and scaliness).

6. Females of childbearing potential must have a negative result for a urinepregnancy test at Day 1 (Visit 1) and must agree to use an adequate method ofbirth control.

7. Able to communicate with the (sub)investigator and understand and comply withthe requirements of the trial.

Exclusion Criteria:

1. Systemic use of biological treatments with a potential effect on psoriasisvulgaris

2. Systemic treatments with all therapies other than biological treatments with apotential effect on psoriasis vulgaris

3. PUVA therapy, UVB therapy or UVA therapy

4. Topical treatment of psoriasis on the areas to be treated with trial medication

5. Topical treatment of psoriasis on the face, genitals or skin folds with vitaminD analogues, potent or very potent corticosteroids or immunosuppressants

6. Topical treatment of conditions other than psoriasis with vitamin D analogues,potent or very potent corticosteroids or immunosuppressants

7. Planned initiation of, or changes in, concomitant medication that may affectpsoriasis vulgaris

8. Patients with any of the following disorders (a) or symptoms (b) present on theareas to be treated with trial medication: (a) viral (e.g., herpes orvaricella) lesions of the skin, fungal, spirochetal or bacterial skininfections, parasitic infections, skin manifestations in relation to syphilisor tuberculosis, rosacea, acne vulgaris, atrophic skin, striae atrophicae,ichthyosis, acne rosacea, ulcers, burns, frostbite, wounds, animal skin disease (scabies, crabs, lice, etc.) or (b) fragility of skin veins.

9. Other inflammatory skin diseases that may confound the evaluation of psoriasisvulgaris.

10. Erythrodermic, exfoliative or pustular psoriasis

11. Planned excessive exposure of areas to be treated with trial medication toeither natural or artificial sunlight

12. Known or suspected disorders of calcium metabolism associated withhypercalcaemia, or albumin-corrected serum calcium above the reference range

13. Known or suspected severe renal insufficiency, severe hepatic disorders orsevere heart disease.

14. Known or suspected hypersensitivity to any components of the investigationalproducts.

15. Clinical signs or symptoms of Cushing's disease or Addison's disease

16. Treatment with any non-marketed drug substance

17. Current participation in any other interventional clinical trial

18. Previously randomised in this trial

19. Females who are pregnant, wishing to become pregnant or are breast-feeding